IBRX has been in the news 500% more than usual
Feb 23, 2026, 7:34 PM
3.25%
What does IBRX do
ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
IBRX has been in the news recently: ImmunityBio, Inc. (NASDAQ: IBRX) released its Q4 earnings on Monday, February 23, 2026 at 7:00 AM and reported significant revenue growth. Although U.S. stocks fell that day with the Dow Jones down about 400 points, IBRX shares rose on the positive earnings news.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.